Chronic Inflammation Induced Immunosuppression Tumor Microenvironment of Oral Cancer
Keywords:
myeloid derived suppressor cells, chronic inflammation, oral cancer, granulocytic monocytic colony stimulating factor, natural killer cells, transform
Abstract
Oral Cancer is a wound that do not heal is a complex disease consists of heterogeneous tissue in their tumor microenvironment. Oral cancer accounts eighth most Common Cancer worldwide. Chronic inflammatory mediators released from immune cells in tumor microenvironment of oral cancer such as macrophages, T lymphocytes, dendritic cells, Natural killer cells release cytokines, Chemokine's and growth factors helps in generation of myeloid derived suppressor cells. Myeloid derived suppressor cells are derived from myeloid progenitor cells of bone marrow secretes inflammatory mediators iNOS, arginase-1, PGE2,IL-10 and IL-4 suppresses adaptive and innate immunity by interacting with macrophages, T-cells, Natural killer cells and dendritic cells favours pro-tumoral activity by activating transcriptional factors (NF-KB,STAT -3,HIF) further progress in to oral cancer. Myeloid derived suppressor cells reduces T cell activation and function by Arginase-1, iNOS, peroxynitrate over expression and cysteine depletion.
Downloads
- Article PDF
- TEI XML Kaleidoscope (download in zip)* (Beta by AI)
- Lens* NISO JATS XML (Beta by AI)
- HTML Kaleidoscope* (Beta by AI)
- DBK XML Kaleidoscope (download in zip)* (Beta by AI)
- LaTeX pdf Kaleidoscope* (Beta by AI)
- EPUB Kaleidoscope* (Beta by AI)
- MD Kaleidoscope* (Beta by AI)
- FO Kaleidoscope* (Beta by AI)
- BIB Kaleidoscope* (Beta by AI)
- LaTeX Kaleidoscope* (Beta by AI)
How to Cite
References
A Pietras K, Ostman (2010) Hallmarks of cancer; Interactions with the tumorstroma. 316, 1324-1331.
T Condamine, I Ramachandran, J Youn, D Gabrilovich (2015) Regulation of tumor metastasis by myeloid-derived suppressor cells. 66, 97-110.
E Peranzoni, S Zilio, I Marigo, L Dolcetti, P Zanovello, S Mandruzzato, V Bronte (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. 22, 238-244.
F Colotta, P Allavena, A Sica, C Garlanda, A Mantovani (2009) Cancer -related inflammation, the seventh hallmark of cancer; links to genetic instability. 30, 1073-1081.
Tania Fiaschi, Paola Chiarugi (2012) Oxidative Stress, Tumor Microenvironment, and Metabolic Reprogramming: A Diabolic Liaison. 2012, 1-8.
H Bauer, T Jung, D Tsikas, D Stichtenoth, C Frölich, C Neumann (1997) Nitric oxide inhibits the secretion of T‐helper 1‐ and T‐helper 2‐associated cytokines in activated human T cells'pa. 90(2), 205-211.
W Sosroseno, P Bird, G Seymour (2009) Effect of exogenous nitric oxide on murine splenic immune response induced by Aggregatibacter actinomycetemcomitans lipopolysaccharide. 15(3), 95-98.
R Bingisser, P Tilbrook, P Holt, Kees U R (1998) Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/ STAT5 signaling pathway. 160, 5729-5734.
Laura Edgington-Mitchell, Belinda Parker (2014) Disparate functions of myeloid-derived suppressor cells in cancer metastasis. 38, 38-77.
P Lejeune, P Lagadec, N Onier, D Pinard, H Ohshima, Jeannin, Jf (1994) Nitric oxide involvement in tumorinduced immunosuppression. 152, 5077-5083.
A Mazzoni, V Bronte, A Visintin, J H Spitzer, E Apolloni, P Serafini, P Zanovello, D Segal (2002) Myeloid suppressor lines inhibit T cell responses by an NOdependent mechanism. 168, 689-695.
Marianne Medot-Pirenne, Michelle Heilman, Malinee Saxena, Patricia Mcdermott, Charles Mills (1999) Augmentation of an Antitumor CTL Response In Vivo by Inhibition of Suppressor Macrophage Nitric Oxide. 163(11), 5877-5882.
Kazuya Sato, Katsutoshi Ozaki, Iekuni Oh, Akiko Meguro, Keiko Hatanaka, Tadashi Nagai, Kazuo Muroi, Keiya Ozawa (2007) Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. 109(1), 228-234.
O Harari, J Liao (2004) Inhibition of MHC II gene transcription by nitric oxide and antioxidants. 10, 893-898.
L Rivoltini, M Carrabba, V Huber, C Castelli, L Novellino, P Dalerba (2002) Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. 188, 97-113.
C Bogdan (2001) Nitric oxide and the immune response. 2, 907-916.
S Morris, Jr (2002) Regulation of Enzymes of Urea and Arginine Synthesis. 12(1), 81-101.
W Zhao, Y Xu, J Xu, D Wu, B Zhao, Z Yin, X Wang (2015) Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially. 26(2), 314-321.
V Bronte, P Serafini, De Santo, C Marigo, I Tosello, V Mazzoni, A (2003) IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. 170, 270-278.
J Medina-Echeverz, F Aranda, P Berraondo (2014) Myeloid-derived cells are key targets of tumor immunotherapy. 3(4), 28-37.
Paulo Rodríguez, Augusto Ochoa (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. 222(1), 180-191.
K Parker, D Beury, S Ostrand-Rosenberg (2015) Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. 12, 25-32.
S Nagaraj, K Gupta, V Pisarev, L Kinarsky, S Sherman, L Kang, D Herber, J Schneck, D Gabrilovich (2007) Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. 13, 828-835.
Jingwei Jiang, Weijian Guo, Xiaohua Liang (2014) Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients. 75(11), 1128-1137.
M Srivastava, P Sinha, V Clements, P Rodriguez, S Ostrand-Rosenberg (2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. 70, 68-77.
A Keskinov, M Shurin (2015) Myeloid regulatory cells in tumor spreading and metastasis. 220(2), 236-242.
S Ostrand -Rosenberg, P Sinha (2009) Myeloidderived suppressor cells: linking inflammation and cancer. 188(8), 4499-4506.
E Eruslanov, I Daurkin, J Ortiz, J Vieweg, S Kusmartsev (2010) Pivotal advance; Tumor -mediated induction of myeloid -derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. 88, 839-848.
D Legler, M Bruckner, E Vetz-Von Allmen, P Krause (2010) Prostaglandin E2 at new glance; Novel insights in functional diversity offer therapeutic chances. 42, 198-201.
Suzanne Ostrand-Rosenberg, Pratima Sinha, Daniel Beury, Virginia Clements (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. 22(4), 275-281.
Nahzli Dilek, Romain Vuillefroy De Silly, Gilles Blancho, Bernard Vanhove (2012) Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance. 3, 208-218.
E Lo Manaco, E Tremante, C Cerboni, E Melluci, L Sibilio, A Zingoni (2011) Human Leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. 13, 822-830.
A Harda, N Sekido, T Akahoshi, T Wada, N Mukaida, K Matsushima (1994) Essential involvement of interleukin -8 (IL-8) in acute inflammation. 56, 559-564.
Q Xu, L Wang, H Li (2012) Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial -mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF-beta. 41, 46-58.
H Wang, J Wu, Y Zhang (2012) Transforming growth factor beta -induced epithelial -mesenchymal transition increases cancer stem -like cells in the PANC-1 cell line. 3, 229-233.
Qingqi Jiang, Sachiko Akashi, Kensuke Miyake, Howard Petty (2000) Cutting Edge: Lipopolysaccharide Induces Physical Proximity Between CD14 and Toll-Like Receptor 4 (TLR4) Prior to Nuclear Translocation of NF-κB. 165(7), 3541-3544.
Y Wang, L Li, X Guo (2012) Interleukin -6(IL-6) signaling regulates anchorage independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. 59, 228-236.
E Tindall, G Severi, N Hoang (2012) Interleukin -6 promoter variants, prostate cancer risk and survival. 72, 1701-1707.
A Mancino, T Schioppa, P Larghi (2008) Divergent effects of hypoxia on dendritic cell functions. 112, 3723-3734.
Angela Elia, Paola Cappello, Maura Puppo, Tiziana Fraone, Cristina Vanni, Alessandra Eva, Tiziana Musso, Francesco Novelli, Luigi Varesio, Mirella Giovarelli (2010) Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile. 84(6), 1472-1482.
Meixiang Yang, Chunhong Ma, Shuxun Liu, Qianqian Shao, Wenjuan Gao, Bingfeng Song, Jintang Sun, Qi Xie, Yun Zhang, Alei Feng, Yanguo Liu, Weixu Hu, Xun Qu (2010) HIF‐dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2‐stimulating phenotype under hypoxia. 88(2), 165-171.
M Douglas, I Dmitry, Gabrilovich (2015) Myeloid derived suppressor cells in the tumor microenvironment; Expect the unexpected. 7, 1125-1135.
I Poschke, Y Mao, L Adamson, F Salazar-Onfray, G Masucci, R Kiessling (2011) Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. 8, 210-213.
B Mckenzie, R Kastelein, D Cua (2006) Understanding the IL-23-IL-17 immune pathway. 27, 17-23.
L Raffaghello, G Bianchi (2014) Myeloid-Derived Suppressor Cells and Tumor Growth. In Interaction of Immune and Cancer Cells. 91-109.
C Diaz-Montero, Jim Finke, Alberto Montero (2014) Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications. 41(2), 174-184.
Michele Teng, Daniel Andrews, Nicole Mclaughlin, Bianca Von Scheidt, Shin Ngiow, Andreas Möller, Geoffrey Hill, Yoichiro Iwakura, Martin Oft, Mark Smyth (2010) IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. 107(18), 8328-8333.
W Sosroseno (2009) Effect of exogenous nitric oxide on murine splenic immune response induced by Aggregatibacteractinomycetemcomitans lipopolysaccharide. 15, 95-98.
R Bingisser (1998) Macrophagederivednitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5signaling pathway. 160, 5729-5734.
P Bobe (1999) Nitric oxide mediation of active immunosuppression associated with graft-versus hostreaction. 94, 1028-1037.
P Lejeune, P Lagadec, N Onier, D Pinard, H Ohshima, J Jeannin (1994) Nitric oxide involvement in tumor-induced immunosuppression.. 152(10), 5077-5083.
A Mazzoni (2002) Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. 168, 689-695.
M Medot-Pirenne (1999) Augmentation of an antitumor CTL response in vivo by inhibition of suppressor macrophage nitric oxide. 163, 5877-5882.
K Sato (2007) Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. 109, 228-234.
Olivier Harari, James Liao (2012) Inhibition of MHC II Gene Transcription by Nitric Oxide and Antioxidants. 10(8), 893-898.
Licia Rivoltini, Matteo Carrabba, Veronica Huber, Chiara Castelli, Luisa Novellino, Piero Dalerba, Roberta Mortarini, Giuseppe Arancia, Andrea Anichini, Stefano Fais, Giorgio Parmiani (2002) Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. 188(1), 97-113.
C Bogdan (2011) Nitric oxide and the immune response. 2, 907-916.
S Morris (2002) Regulation of enzymes of the urea cycle and arginine metabolism. 22, 87-105.
Guoyao Wu, Sidney Morris (1998) Arginine metabolism: nitric oxide and beyond. 336(1), 1-17.
V Bronte (2003) IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. 170, 270-278.
V Bronte (2005) Regulation of immune responses by L-arginine metabolism. 5, 641-654.
P Rodriguez (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. 222, 180-191.
P Rodriguez (2004) Arginase -1 production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigenspecific T-cell responses. 64, 5839-5849.
S Nagaraj (2007) Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. 13, 828-835.
P Gout (2011) A potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: anew action for an old drug. 15, 1633-1640.
Minu Srivastava, Pratima Sinha, Virginia Clements, Paulo Rodriguez, Suzanne Ostrand-Rosenberg (2010) Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine. 70(1), 68-77.
Anton Keskinov, Michael Shurin (2015) Myeloid regulatory cells in tumor spreading and metastasis. 220(2), 236-242.
S Ostrand -Rosenberg (2009) Myeloidderived suppressor cells: linking inflammation and cancer. 188, 4499-4506.
Evgeniy Eruslanov, Irina Daurkin, Javier Ortiz, Johannes Vieweg, Sergei Kusmartsev (2010) Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. 88(5), 839-848.
D Legler (2010) Prostaglandin E2 at new glance; Novel insights in functional diversity offer therapeutic chances. 42, 198-201.
S Ostrand -Rosenberg (2012) Cross-talk between myeloid -derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor -induced immune suppression. 22, 275-281.
N Dilek (2014) Myeloid -derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance. 3, 208-214.
E Lo Manaco (2011) Human Leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. 13, 822-830.
A Harda (1994) Essential involvement of interleukin -8 (IL-8) in acute inflammation. 56, 559-564.
Q Xu (2012) Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial -mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF-beta. 41, 46-58.
Hui Wang, Junli Wu, Y Zhang, Xiaofeng Xue, Dong Tang, Zhongxu Yuan, Minyong Chen, Jishu Wei, Jingjing Zhang, Y Miao (2012) Transforming growth factor β-induced epithelial-mesenchymal transition increases cancer stem-like cells in the PANC-1 cell line. 3(1), 229-233.
Y Wang (2012) Interleukin -6(IL-6) signaling regulates anchorage independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. 59, 228-236.
E Tindall (2012) Interleukin -6 promoter variants, prostate cancer risk and survival. 72, 1701-1707.
A Mancino (2008) Divergent effects of hypoxia on dendritic cell functions. 112, 3723-3734.
A Elia (2010) Human dendritic cells differentiated in hypoxia down modulate antigen uptake and change their chemokine expression profile. 84, 165-171.
M Yang (2010) HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2 -stimulating phenotype under hypoxia. 88, 165-171.
D Gabrilovich (2014) Mechanisms and functional significance of tumour-induced dendriticcell defects. 4, 941-952.
I Poschke, Y Mao, L Adamson, F Salazar-Onfray, G Masucci, R Kiessling (2011) Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. 61(6), 827-838.
B Mckenzie (2006) Understanding the IL-23-IL-17 immune pathway. 27, 17-23.
C Langrish (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. 201, 233-240.
J Langowski (2006) IL-23 promotes tumour incidence and growth. 442, 461-465.
D Mittal (2014) New insights into cancer immunoediting and its three component phaseselimination, equilibrium and escape. 27, 16-25.
Published
2016-10-08
Issue
Section
License
Copyright (c) 2016 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.